Literature DB >> 15014638

Impact of Antipsychotics on Geriatric Patients: Efficacy, Dosing, and Compliance.

Gerald A. Maguire1.   

Abstract

People today are living longer. Old age is the number one risk factor for dementia, which is often associated with behavioral disturbances and psychosis as well as cognitive and memory impairment. Elderly persons with dementia-particularly those who are agitated or aggressive-are often placed in nursing homes and consequently treated with antipsychotic medications. Most of the studies of antipsychotic efficacy and safety have been conducted in young schizophrenic patients, but there are differences in dosing schedules, efficacy, and compliance when these drugs are used in elderly patients with dementia and psychosis. A review of both nonpharmacologic and pharmacologic treatment is herewith presented for the treatment of elderly dementia patients, especially those living in long-term care facilities.

Entities:  

Year:  2000        PMID: 15014638      PMCID: PMC181134          DOI: 10.4088/pcc.v02n0503

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  30 in total

1.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.

Authors:  I R Katz; D V Jeste; J E Mintzer; C Clyde; J Napolitano; M Brecher
Journal:  J Clin Psychiatry       Date:  1999-02       Impact factor: 4.384

2.  Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.

Authors:  C M Beasley; M A Dellva; R N Tamura; H Morgenstern; W M Glazer; K Ferguson; G D Tollefson
Journal:  Br J Psychiatry       Date:  1999-01       Impact factor: 9.319

3.  Prospective study of tardive dyskinesia incidence in the elderly.

Authors:  B L Saltz; M G Woerner; J M Kane; J A Lieberman; J M Alvir; K J Bergmann; K Blank; J Koblenzer; K Kahaner
Journal:  JAMA       Date:  1991-11-06       Impact factor: 56.272

4.  Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.

Authors:  G D Tollefson; C M Beasley; R N Tamura; P V Tran; J H Potvin
Journal:  Am J Psychiatry       Date:  1997-09       Impact factor: 18.112

5.  A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia.

Authors:  J Peuskens; C G Link
Journal:  Acta Psychiatr Scand       Date:  1997-10       Impact factor: 6.392

Review 6.  Treatment strategies for agitation and psychosis in dementia.

Authors:  P N Tariot
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384

7.  Risperidone-induced galactorrhea associated with a prolactin elevation.

Authors:  A Popli; S Gupta; S R Rangwani
Journal:  Ann Clin Psychiatry       Date:  1998-03       Impact factor: 1.567

Review 8.  Management of the agitated elderly patient in the nursing home: the role of the atypical antipsychotics.

Authors:  S D Verma; D A Davidoff; K K Kambhampati
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

9.  Prolactogenic effects of risperidone in male patients--a preliminary study.

Authors:  R S Shiwach; T J Carmody
Journal:  Acta Psychiatr Scand       Date:  1998-07       Impact factor: 6.392

10.  Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.

Authors:  S S Rich; J H Friedman; B R Ott
Journal:  J Clin Psychiatry       Date:  1995-12       Impact factor: 4.384

View more
  2 in total

Review 1.  Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?

Authors:  A Gurevich; V Guller; Y N Berner; S Tal
Journal:  J Nutr Health Aging       Date:  2012       Impact factor: 4.075

2.  Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Authors:  Ramón Cacabelos
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.